AbbVie will acquire Apogee Therapeutics for $10.9 billion in cash, a major biotech deal that expands AbbVie's next-generation immunology pipeline. The transaction is strategically positive for AbbVie and underscores continued M&A activity in healthcare and biotech. The news is likely to support sentiment for both companies and the broader biotech deal space.
AbbVie will acquire Apogee Therapeutics for $10.9 billion in cash, a major biotech deal that expands AbbVie's next-generation immunology pipeline. The transaction is strategically positive for AbbVie and underscores continued M&A activity in healthcare and biotech. The news is likely to support sentiment for both companies and the broader biotech deal space.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately positive
Sentiment Score
0.72
Ticker Sentiment
